

Nectar Lifesciences Ltd.

Ref No. NLL/CS/2012-49

Dated: 14.05.2012

1. National Stock Exchange of India Limited
'G' Block, Exchange Plaza, Bandra Kurla Complex,
Bandra (East), MUMBAI - 400 051.
2. Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
MUMBAI - 400 001.

Sub: Compliance under Clause 41 the Listing Agreement.

Sirs,

Pursuant to Clause 41 of the Listing Agreement, please find enclosed herewith a copy of the Unaudited Financial Results for the quarter ended on 31st March, 2012, as approved by the Board of Directors in their meeting held on even date i.e. 14th May, 2012.

Kindly take the same on record and oblige.

Thanking you,

Yours truly,

For Nectar Lifesciences Limited


Sunder Lal
Company Secretary

Encl. as above

CC:- Societe de la Bourse de Luxembourg S.A.
BP 165, L-2011 Luxembourg,
Telephone : (00352) 47 79 38-1
Fax: (00352) 47 32 98



NECTAR LIFESCIENCES LIMITED

Regd. Office: VIII, Saidpura, Tehsil Derabassi, Distt. Mohali, (Punjab)

Part I - Statement of Standalone Unaudited for the Quarter and Year Ended 31.03.2012

(Rs in Lacs)

S. No	PARTICULARS	Quarter ended 31.03.2012	Quarter ended 31.12.2011	Quarter ended 31.03.2011	Year ended 31.03.2012	Year ended 31.03.2011
		Unaudited	Unaudited	Audited	Unaudited	Audited
1.	Income from Operations					
	Gross Sales	40567.83	41711.79	35644.91	134124.19	111577.03
	Less : Excise Duty	1188.27	719.24	1840.71	3845.04	6032.19
	(a) Net Sales	39379.56	40992.55	33804.20	130279.15	105544.84
	(b) Other Operating Income	311.00	154.47	215.90	954.60	661.44
	Total Income from Operations (net)	39690.56	41157.02	34020.10	131233.75	106206.28
2.	Expenses					
	(a) Cost of Materials consumed	32435.05	31291.82	24255.62	101678.82	71039.76
	(b) Purchase of Stock in Trade	1679.71	1616.37	4153.06	6067.66	8299.68
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(5351.91)	(3731.72)	(3854.14)	(16411.91)	(8232.45)
	(d) Employee benefits expense	1029.97	1221.82	848.28	4726.53	3716.81
	(e) Depreciation and amortisation expense	1431.86	1663.36	1174.09	5929.13	4609.59
	(f) Other expenses	3048.38	3288.82	2683.20	10642.12	8694.38
	Total Expenses	34273.06	35350.47	29260.11	112632.35	88127.77
3.	Profit from Operations before Other Income, finance costs and exceptional Items (1-2)	5417.50	5806.55	4759.99	18601.40	18078.51
4.	Other Income	372.78	412.18	1327.34	1235.61	1345.58
5.	Profit before finance costs and exceptional Items (3+4)	5790.28	6218.73	6087.33	19837.01	19424.09
6.	Finance costs	3754.96	2542.82	3222.73	10365.91	7408.40
7.	Profit after finance costs but before exceptional Items (5-6)	2035.32	3675.91	2864.60	9471.10	12015.69
8.	Exceptional Items	0.00	0.00	0.00	0.00	0.00
9.	Profit from ordinary activities before tax (7+8)	2035.32	3675.91	2864.60	9471.10	12015.69
10.	Tax Expense	490.33	436.94	(411.69)	1434.87	1734.68
11.	Net Profit from ordinary activities after tax (9-10)	1544.99	3238.97	3276.29	8036.23	10281.01
12.	Extraordinary Item (net of tax expense)	0.00	0.00	0.00	0.00	0.00
13.	Net Profit for the period (11-12)	1544.99	3238.97	3276.29	8036.23	10281.01
14.	Paid up Equity Share Capital (Face Value per share : Re.1/-)	2242.61	2242.61	2242.61	2242.61	2242.61
15.	Reserves excluding Revaluation Reserves					69875.75
16.i	Earnings per Share (EPS)					
	Basic EPS before Extraordinary items	0.69	1.44	1.46	3.58	4.63
	Diluted EPS before Extraordinary items	0.69	1.44	1.46	3.58	4.63
	Basic EPS after Extraordinary items	0.69	1.44	1.46	3.58	4.63
	Diluted EPS after Extraordinary items	0.69	1.44	1.46	3.58	4.63

Part II Select Information for the Quarter and Year Ended 31.03.2012

A Particulars of shareholding						
1.	Public Shareholding					
	- Number of Shares	124792970	124856970	124969970	124792970	124969970
	- Percentage of Shareholding	55.65	55.67	55.73	55.65	55.73
2.	Promoters and Promoter Group Shareholding					
	a) Pledged/Encumbered					
	- Number of Shares	0	0	0	0	0
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	0.00	0.00	0.00	0.00	0.00
	- Percentage of Shares (as a % of the total share capital of the company)	0.00	0.00	0.00	0.00	0.00
	b) Non-encumbered					
	- Number of Shares	99468000	99404000	99291000	99468000	99291000
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the company)	44.35	44.33	44.27	44.35	44.27

B Investor Complaints		3 Months ended 31.03.2012				
	Pending at the beginning of Quarter				0	
	Received During the Quarter				13	
	Disposed Off During the Quarter				13	
	Pending at the end of Quarter				0	

Notes:

- The above financial results were reviewed by Audit Committee on 14.05.2012 and approved by the Board in its meeting held on even date i.e. 14.05.2012 and further limited reviewed by the Statutory Auditors of the Company.
- The company is exclusively in the pharmaceutical business
- The above financial results are on stand alone basis.
- As required by the Accounting Standard -11 on "The effect of change in foreign exchange rates", loss on foreign currency loans for the financial year 2011-12 has been recognised in the current quarter ended March 2012.

By Order of the Board of Directors
of Nectar Lifesciences Limited

Sd/-
(Dinesh Dua)
Chief Executive Officer & Director

Dated: 14.05.2012

Place: Chandigarh